United States Federal Circuit

Affirmed that a pharmaceutical company's patent claims in a multiple sclerosis drug were invalid for obviousness. Several competitors seeking to market a generic version of the same drug raised the issue of obviousness when the company sued them for infringement. In a 2-1 decision, the Federal Circuit affirmed that the patent claims in question were invalid.

Appellate Information

• Published 2018/09/10

Judges

• Taranto

Court

• United States Federal Circuit

Counsel